Frontlight ResearchEarly access
TerminatedPhase 1/2
APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
Key facts
- Who runs it
- Ascentage Pharma Group Inc.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1/2
- People taking part
- 21 people enrolled
- Started
- 17 Mar 2021
- Ended
- 10 Dec 2024
- Type of study
- Interventional
- Treatments tested
- APG-1387 for Injection
- Gemcitabine
- Nab paclitaxel
- Record updated
- 8 January 2026
- Why it stopped
- Company Strategy
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Subjects must be ≥18 years of age at time of informed consent
- Able to comply with the study protocol, in the investigator's judgment
- Expected survival ≥ 3 months
- Histology or cytology confirmed as advanced pancreatic adenocarcinoma, and:; Standard treatment failed or intolerant to standard treatment(Phase Ib); First line standard treatment failed (Phase II)
- ECOG 0-1
- Adequate organ function
- Subjects must have at least one measurable lesion evaluated by Computed Tomography (CT) scan on RECIST ver.1.1 at pre-treatment
Who cannot take part
- Has had chemotherapy, radiation, target or other antitumor therapy within 14 days prior to the first dose of study drug
- Has received an investigational agent or used an investigational device within 28 days of the first dose of study drug
- Has received a therapy with TNFα within 28 days of the first dose of study drug
- Has received IAP-inhibitor before
- Has had major surgery within 28 days of dosing of investigational agent, or minor surgery within 14 days
- Patients with clinically evident Hepatitis B surface antigen (HBs) positive, Hepatitis C virus (HCV) antibody positive, Human Immunodeficiency Virus (HIV) antibody positive
- Known active central nervous system involvement
- Pregnant or breastfeeding (lactating) women
- Other situations that investigator think not suit for study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a two stage study consisting of a dose escalation phase Ib and a phase II study which include subjects with previously-treated, advanced pancreatic adenocarcinoma. Dose Limiting Toxicities (DLTs) and maximum tolerated dose (MTD) of APG1387 in combination with nab-paclitaxel and gemcitabine will be evaluated in the dose escalation phase Ib. Safety and efficacy of APG1387 plus gemcitabine and nab-paclitaxel will be evaluated in phase II.
The group in the trial
- APG1387 in combination with Gemcitabine and Nab-PaclitaxelTreatment being tested
Treatment: APG-1387 for Injection, Gemcitabine, and Nab paclitaxel
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open Label, Multiple Centers Phase Ib/II Study of APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
- Publications
- Record updated
- 8 January 2026